Drugs for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 158)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Doxorubicin |
Approved, Investigational |
Phase 4 |
|
23214-92-8 |
31703 |
|
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-hydroxydaunomycin
14-Hydroxydaunomycin
14-hydroxydaunorubicine
14-Hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
adiblastine (hydrochloride salt)
ADM
ADR
adr iablatina (hydrochloride salt)
Adriablastin
Adriablastine
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin semiquinone
Adriamycin Semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (hydrochloride salt)
Adriblastina (TN)
Adriblastine
adriblatina (hydrochloride salt)
Adrimedac
Aerosolized Doxorubicin
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
BPBio1_000502
BRD-K92093830-003-04-3
Bristol-myers squibb brand OF doxorubicin hydrochloride
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
Caelyx
CCRIS 739
Cell pharm brand OF doxorubicin hydrochloride
CHEBI:28748
CHEMBL179
CID31703
Columbia brand OF doxorubicin hydrochloride
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
Doxil
Doxo
Doxo cell
Doxo-cell
Doxolem
doxorubicin
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
|
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
Doxorubicin Hydrochloride
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
DOX-SL
EINECS 245-495-6
Elan brand OF doxorubicin hydrochloride
Farmablastina (hydrochloride salt)
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
FI 106
Hexal brand OF doxorubicin hydrochloride
HMS2089H06
HSDB 3070
Hydrochloride, doxorubicin
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
LMPK13050001
LS-1029
LS-165655
Medac brand OF doxorubicin hydrochloride
MLS000759533
Myocet
NChemBio.2007.10-comp13
nchembio809-comp5
NCI-C01514
NDC 38242-874
Neocorp brand OF doxorubicin hydrochloride
NIOSH/JT9100000
NSC 123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
Tedec meiji brand OF doxorubicin hydrochloride
ThermoDox
TLC D-99
Triferric doxorubicin
UNII-80168379AG
Urokit doxo cell
Urokit doxo-cell
|
|
| 2 |
|
Hematinics |
|
Phase 4 |
|
|
|
| 3 |
|
Epoetin alfa |
|
Phase 4 |
|
113427-24-0 |
|
| 4 |
|
Liposomal doxorubicin |
|
Phase 4 |
|
|
31703 |
|
Synonyms:
|
|
LipoDox
liposomal doxorubicin
Pegylated Liposomal Doxorubicin Hydrochloride
|
|
| 5 |
|
Iron |
Approved |
Phase 3 |
|
7439-89-6 |
23925 29936 |
|
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
|
Fe
FE
FE (III) ion
Fe(3+)
Fe(III)
Fe1+
Fe-40
fer
Feronate
Ferretts
Ferric ion
Ferric iron
Ferro-Caps
Ferro-Time
ferrous iron
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(3+)
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
Siderol
SUY-B 2
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
|
|
| 6 |
|
Darbepoetin alfa |
Approved, Investigational |
Phase 3 |
|
209810-58-2, 11096-26-7 |
|
|
Synonyms:
Darbepoetin
Darbepoetin alfa,recombinant
|
|
|
| 7 |
|
Ketamine |
Approved, Vet_approved |
Phase 3 |
|
6740-88-1 |
3821 |
|
Synonyms:
(-)-Ketamine
(+-)-Ketamine
(+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-Ketamine
(±)-ketamine
(S)-(-)-Ketamine
(S)-Ketamine
100477-72-3
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone
2-(O-Chlorophenyl)-2-(methylamino)-cyclohexanone
33643-45-7
6740-88-1
79499-51-7
AC1L1GSH
AC1Q40UR
AKOS001053247
BRN 2216965
C07525
C13H16ClNO
Calipsol
Calypsol
Cetamina
Cetamina [INN-Spanish]
CHEBI:138833
CHEBI:6121
CHEMBL742
CI 581 base
CI-581
CID3821
CLSTA 20
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI)
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI)
Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)
D08098
DB01221
DEA No. 7285
DivK1c_000217
dl-Ketamine
|
DL-ketamine
DL-Ketamine
EINECS 229-804-1
Esketamine
Green
IDI1_000217
Kalipsol
KBio1_000217
Ketaject
Ketalar
Ketalar base
Ketamina
ketamine
Ketamine
Kétamine
Ketamine (INN)
Ketamine [INN:BAN]
Ketamine base
Ketamine Base
Ketamine HCL
KETAMINE HCL
Ketamine hydrochloride
Ketaminum
Ketaminum [INN-Latin]
Ketanest
Ketaset
Ketoject
Ketolar
l-Ketamine
L-Ketamine
LS-57301
MLS001331674
MolPort-001-838-070
NCGC00159480-02
NCGC00159480-03
NINDS_000217
NMDA
NSC 70151
NSC70151
SMR000238141
Special K
Special K [street name]
T385
Tekam
Tekam (TN)
UNII-690G0D6V8H
|
|
| 8 |
|
Amitriptyline |
Approved |
Phase 3 |
|
50-48-6 |
2160 |
|
Synonyms:
[3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine
10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene
10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,D)cycloheptene
10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene
10,11-Dihydro-5-(g-dimethylaminopropylidene)-5H-dibenzo(a,D)cycloheptene
10,11-dihydro-5-(γ-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene
10,11-Dihydro-5-(γ-dimethylaminopropylidene)-5H-dibenzo(a,D)cycloheptene
10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine
10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,D)heptalene-Delta(5),gamma-propylamine
10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,D)heptalene-delta(5),g-propylamine
10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,D)heptalene-δ(5),g-propylamine
10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,D)heptalene-δ(5),γ-propylamine
10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-Δ5,γ-propylamine
17086-03-2 (pamoate (2:1))
3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin
3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine
3-(10,11-Dihydro-5H-dibenzo(a,D)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine
3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine
3-(10,11-Dihydro-5H-dibenzo[a,D]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine
30227-34-0 (maleate (1:1))
5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene
5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene
5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,D)cycloheptatriene
5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,D)cycloheptene
5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene
5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene
5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene
5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene
5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene
5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene
5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,D][1,4]cycloheptadiene
5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene
5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene
5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene
5-(g-Dimethylaminopropylidene)-5H-dibenzo[a,D][1,4]cycloheptadiene
5-(γ-dimethylaminopropylidene)-5H-dibenzo[a,d][1,4]cycloheptadiene
5-(Γ-dimethylaminopropylidene)-5H-dibenzo[a,D][1,4]cycloheptadiene
50-48-6
549-18-8 (hydrochloride)
AB00514631
AC1L1D20
Adepress
Adepril
AKOS000512694
Alphapharm brand OF amitriptyline hydrochloride
Amineurin
Amitid
Amitril
Amitrip
Amitriprolidine
Amitriptilina
Amitriptilina [INN-Spanish]
Amitriptilina [Italian]
Amitriptylin
Amitriptylin [German]
Amitriptylin beta
Amitriptylin desitin
Amitriptylin neuraxpharm
Amitriptylin RPH
amitriptyline
Amitriptyline
Amitriptyline (INN)
Amitriptyline [INN:BAN]
Amitriptyline HCL
Amitriptyline hydrochloride
Amitriptyline Hydrochloride
Amitriptylinneuraxpharm
Amitriptylin-neuraxpharm
Amitriptylinum
Amitriptylinum [INN-Latin]
Amitrol
Amitryptiline
Amitryptyline
Amrad brand OF amitriptyline hydrochloride
Amytriptiline
Amytriptylin
Anapsique
Apo amitriptyline
Apo-amitriptyline
ApoAmitriptyline
Apotex brand OF amitriptyline hydrochloride
APS brand OF amitriptyline hydrochloride
BAS 00269727
Bayer brand OF amitriptyline hydrochloride
beta, Amitriptylin
Betapharm brand OF amitriptyline hydrochloride
BIDD:GT0115
BPBio1_000317
BRD-K53737926-003-05-4
BRN 2217885
BSPBio_000287
BSPBio_001836
C06824
Cahill may roberts brand OF amitriptyline embonate
Cahill may roberts brand OF amitriptyline hydrochloride
CAS-549-18-8
CCRIS 9174
CHEBI:2666
CHEMBL629
CID2160
cMAP_000001
|
D07448
Damilan
Damilen
dAmitriptyline
Damitriptyline
DB00321
DDSA brand OF amitriptyline hydrochloride
Desitin brand OF amitriptyline hydrochloride
Desitin, amitriptylin
DivK1c_000766
Domical
Douglas brand OF amitriptyline hydrochloride
EINECS 200-041-6
Elanil
Elavil
Endep
Flavyl
Goldshield brand OF amitriptyline hydrochloride
Hexal brand OF amitriptyline hydrochloride
Hexathane
Horizon
IDI1_000766
KBio1_000766
KBio2_000424
KBio2_002261
KBio2_002992
KBio2_004829
KBio2_005560
KBio2_007397
KBio3_001336
KBio3_002741
KBioGR_000592
KBioGR_002261
KBioSS_000424
KBioSS_002262
Krewel brand OF amitriptyline hydrochloride
L001041
Lantron
Laroxil
Laroxyl
Laroxyl (TN)
Lentizol
Lopac0_000112
Lopac-A-8404
LS-60747
Lundbeck brand OF amitriptyline hydrochloride
Merck brand OF amitriptyline hydrochloride
Merck sharp and dohme brand OF amitriptyline embonate
Merck sharp and dohme brand OF amitriptyline hydrochloride
MK 230
MolPort-001-662-651
N 750
NCGC00015095-01
NCGC00015095-02
NCGC00015095-03
NCGC00015095-10
NCGC00024433-04
Neuraxpharm brand OF amitriptyline hydrochloride
Neuro hexal brand OF amitriptyline hydrochloride
NINDS_000766
Novoprotect
NSC169910
Oprea1_479304
Parke davis brand OF amitriptyline hydrochloride
PDSP1_001564
PDSP2_001548
Prestwick0_000074
Prestwick1_000074
Prestwick2_000074
Prestwick3_000074
Proheptadiene
Protea brand OF amitriptyline hydrochloride
Psicofarma brand OF amitriptyline hydrochloride
Redomex
Rhône poulenc rorer brand OF amitriptyline hydrochloride
Rhône-poulenc rorer brand OF amitriptyline hydrochloride
Ro 4-1575
Roche brand OF amitriptyline hydrochloride
Rodleben brand OF amitriptyline hydrochloride
RPH, Amitriptylin
Saroten
Sarotex
Seroten
SPBio_000082
SPBio_002208
Spectrum_000044
Spectrum2_000101
Spectrum3_000298
Spectrum4_000146
Spectrum5_000806
STK525215
STOCK1S-56825
Sylvemid
Syneudon
TP0
Triptafen
Triptanol
Triptilin
Triptisol
Tryptanol
Tryptine
Tryptizol
UNII-1806D8D52K
Zeneca brand OF amitriptyline hydrochloride
|
|
| 9 |
|
Baclofen |
Approved |
Phase 3 |
|
1134-47-0 |
2284 |
|
Synonyms:
( inverted question mark)-Baclofen
(?)-Baclofen
(+-)-Baclofen
(+/-)- beta-(Aminoethyl)-4- chlorobenzenepropanoic acid
(+/-)-BACLOFEN
(+/-)-beta-(Aminomethyl)-4-chlorobenzenepropanoic acid
1134-47-0
4-Amino-3-(4-chlorophenyl)butanoic acid
4-Amino-3-(4-chlorophenyl)butyrate
4-Amino-3-(4-chlorophenyl)butyric acid
62594-36-9
AB00051921
AC1L1DC6
AC-4530
Alphapharm brand OF baclofen
Alphapharm Brand of Baclofen
Apo baclofen
Apo Baclofen
Apo-baclofen
ApoBaclofen
Apo-Baclofen
Apotex brand OF baclofen
Apotex Brand of Baclofen
Ashbourne brand OF baclofen
Ashbourne Brand of Baclofen
ASTA medica brand OF baclofen
ASTA Medica Brand of Baclofen
Athena brand OF baclofen
Athena Brand of Baclofen
Atrofen
AWD, baclofen
AWD, Baclofen
B 5399
b-(4-Chlorophenyl)gaba
b-(Aminomethyl)-4-chlorobenzenepropanoate
b-(Aminomethyl)-4-chlorobenzenepropanoic acid
b-(Aminomethyl)-p-chlorohydrocinnamate
b-(Aminomethyl)-p-chlorohydrocinnamic acid
b-(p-Chlorophenyl)-g-aminobutyrate
b-(p-Chlorophenyl)-g-aminobutyric acid
B3343
B5399_SIGMA
Ba 34647
Ba34,647
Ba-34,647
Ba34647
Ba-34647
baclofen
Baclofen
Baclofen (JP15/USP/INN)
Baclofen (R,S)
Baclofen [USAN:INN:BAN:JAN]
Baclofen alphapharm brand
Baclofen Alphapharm Brand
Baclofen apotex brand
Baclofen Apotex Brand
Baclofen ashbourne brand
Baclofen Ashbourne Brand
Baclofen athena brand
Baclofen Athena Brand
Baclofen awd
Baclofen AWD
Baclofen ciba-geigy brand
Baclofen Ciba-Geigy Brand
Baclofen irex brand
Baclofen Irex Brand
Baclofen isis brand
Baclofen Isis Brand
Baclofen medtronic brand
Baclofen Medtronic Brand
Baclofen novartis brand
Baclofen Novartis Brand
Baclofen nu-pharm brand
Baclofen Nu-Pharm Brand
Baclofen pharmascience brand
Baclofen Pharmascience Brand
Baclofene
Baclofène
Baclofene [INN-French]
Baclofene Irex
Baclofène irex
BaclofeneIrex
Baclofene-Irex
Baclofène-irex
BaclofèneIrex
Baclofeno
Baclofeno [INN-Spanish]
Baclofenum
Baclofenum [INN-Latin]
Baclon
Baclophen
Baclospas
Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-(9CI)
beta-(4-Chlorophenyl)gaba
beta-(Aminomethyl)-4-chlorobenzenepropanoate
beta-(Aminomethyl)-4-chlorobenzenepropanoic acid
beta-(Aminomethyl)-p-chlorohydrocinnamate
beta-(Aminomethyl)-p-chlorohydrocinnamic acid
beta-(p-Chlorophenyl)-gamma-aminobutyrate
beta-(p-Chlorophenyl)-gamma-aminobutyric acid
Biomol-NT_000251
BPBio1_000012
BPBio1_000750
BRD-A84174873-001-05-2
BRN 2104494
BSPBio_000010
BSPBio_001880
C 34647Ba
C10H12ClNO2
CCRIS 3722
CHEBI:2972
CHEMBL701
Chlorophenyl gaba
Chlorophenyl GABA
Ciba 34,647-Ba
Ciba geigy brand OF baclofen
Ciba Geigy Brand of Baclofen
CIBA34,647ba
|
CIBA-34,647-ba
CIBA34,647BA
CIBA-34,647-BA
Ciba-geigy brand OF baclofen
Ciba-Geigy Brand of Baclofen
CID2284
Clofen
D001418
D00241
DB00181
DivK1c_000001
DL-4-Amino-3-p-chlorophenylbutanoate
DL-4-Amino-3-p-chlorophenylbutanoic acid
DL-Baclofen
EINECS 214-486-9
EU-0100163
GABA, chlorophenyl
GABA, Chlorophenyl
Gabalon
g-Amino-b-(p-chlorophenyl)butyrate
g-Amino-b-(p-chlorophenyl)butyric acid
gamma-Amino-beta-(p-chlorophenyl)butyrate
gamma-Amino-beta-(p-chlorophenyl)butyric acid
Gen baclofen
Gen Baclofen
Gen-baclofen
GenBaclofen
Gen-Baclofen
Genpharm
HMS1568A12
HMS1920E21
HMS2091M03
HMS500A03
I01-1934
IDI1_000001
Irex brand OF baclofen
Irex Brand of Baclofen
Isis brand OF baclofen
Isis Brand of Baclofen
KBio1_000001
KBio2_000466
KBio2_003034
KBio2_005602
KBio3_001380
KBioGR_000650
KBioSS_000466
Kemstro
Kemstro (TN)
L000002
Lebic
Lioresal
Liorésal
Lioresal (TN)
Lioresal Intrathecal
Lopac0_000163
LS-77134
Medtronic brand OF baclofen
Medtronic Brand of Baclofen
MLS000028480
MolPort-002-051-370
NCGC00015156-05
NCGC00015156-12
NCGC00023843-03
NCGC00024579-03
NCGC00024579-04
NCGC00024579-05
NCGC00024579-06
NINDS_000001
Novartis brand OF baclofen
Novartis Brand of Baclofen
NSC329137
Nu baclo
Nu Baclo
Nu pharm brand OF baclofen
Nu Pharm Brand of Baclofen
Nu-baclo
NuBaclo
Nu-Baclo
Nu-Baclofen
Nu-pharm brand OF baclofen
Nu-Pharm Brand of Baclofen
Oprea1_440627
PCP-GABA
Pharmascience brand OF baclofen
Pharmascience Brand of Baclofen
PMS Baclofen
Pms-Baclofen
PMSBaclofen
PMS-Baclofen
Prestwick_85
Prestwick0_000085
Prestwick1_000085
Prestwick2_000085
Prestwick3_000085
SMP1_000036
SMR000058294
SPBio_000044
SPBio_001949
Spectrum_000066
SPECTRUM1500135
Spectrum2_000092
Spectrum3_000310
Spectrum4_000245
Spectrum5_000852
STK535284
STOCK2S-30552
UNII-H789N3FKE8
UPCMLD-DP142
UPCMLD-DP142:001
Î’-(4-chlorophenyl)gaba
Î’-(aminomethyl)-4-chlorobenzenepropanoate
Î’-(aminomethyl)-4-chlorobenzenepropanoic acid
Î’-(aminomethyl)-p-chlorohydrocinnamate
Î’-(aminomethyl)-p-chlorohydrocinnamic acid
Β-(p-chlorophenyl)-γ-aminobutyrate
Β-(p-chlorophenyl)-γ-aminobutyric acid
Γ-amino-β-(p-chlorophenyl)butyrate
Γ-amino-β-(p-chlorophenyl)butyric acid
|
|
| 10 |
|
Perphenazine |
Approved |
Phase 3 |
|
58-39-9 |
4748 |
|
Synonyms:
.gamma.-[4-(.beta.-Hydroxyethyl)piperazin-1-yl]propyl-2-chlorophenothiazine
1-(2-Hydroxyethyl)-4-(3-(2-chloro-10-phenothiazinyl)propyl)piperazine
1-(2-Hydroxyethyl)-4-[3-(2-chloro-10-phenothiazinyl)propyl]piperazine
1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina
1',1-(2-Idrossietil)-4,3-(2-cloro-10-fenotiazil)propilpiperazina [Italian]
1-Piperazineethanol, 4-[3-(2-chlorophenothiazin-10-yl)propyl]-, trihydrochloride
2-(4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol
2-(4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazinyl)ethanol
2-[4-[3-(2-Chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol
2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol
2-{4-[3-(2-Chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol
2-Chloro-10-(3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine
2-chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine
2-Chloro-10-(3-(4-(2-hydroxyethyl)piperazin-1-yl)propyl)phenothiazine
2-Chloro-10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazine
2-Chloro-10-3-(1-(2-hydroxyethyl)-4-piperazinyl)propyl phenothiazine
2-Chloro-10-3-[1-(2-hydroxyethyl)-4-piperazinyl]propyl phenothiazine
4-(3-(2-Chlorophenothiazin-10-yl)propyl)-1-piperazineethanol
4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol
4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol
4-[3-(2-chlorophenothiazin-10-yl)propyl]-1-piperazineethanol
4-[3-(2-Chlorophenothiazin-10-yl)propyl]-1-piperazineethanol
58-39-9
AB00052390
AC-12196
AC1L1IVB
AI3-50151
AKOS000664046
Apo-Perphenazine
BAS 00139131
BIDD:GT0150
BPBio1_000188
BRD-K10995081-001-05-5
BSPBio_000170
BSPBio_002376
C07427
C21H26ClN3OS
CAS-58-39-9
CHEBI:8028
CHEMBL567
Chlorperphenazine
Chlorpiprazine
CID4748
CPD000058180
D00503
D010546
DB00850
Decentan
DivK1c_000880
EINECS 200-381-5
Emesinal
Etaperazin
Etaperazine
Ethaperazine
Etrafon-A
Etrafon-Forte
EU-0072164
EU-0100930
Fentazin
F-mon
F-Mon
g-(4-(b-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine
gamma-(4-(beta-Hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine
HMS1568I12
HMS1922M14
HMS2093M15
HMS502L22
HSDB 3379
I06-1508
IDI1_000880
KBio1_000880
KBio2_002090
KBio2_004658
|
KBio2_007226
KBio3_001596
KBioGR_001445
KBioSS_002090
L000919
Lopac0_000930
Lopac-P-6402
LS-112185
MLS000069637
MLS001146929
MolPort-001-727-942
NCGC00015826-01
NCGC00015826-02
NCGC00015826-03
NCGC00015826-06
NCGC00015826-10
NCGC00024092-03
NCGC00024092-04
NCGC00024092-05
NCGC00024092-06
nchembio873-comp26
NINDS_000880
NSC 150866
NSC150866
Oprea1_603835
P 6402
P6402_SIGMA
Perfenazina
Perfenazina [INN-Spanish]
Perfenazina [Italian]
Perfenazine
Perphenan
Perphenazin
perphenazine
Perphenazine
Perphénazine
Perphenazine (JP15/USP/INN)
Perphenazine [INN:BAN:JAN]
Perphenazine [Trilafon]
Perphenazine maleate
Perphenazinum
Perphenazinum [INN-Latin]
Prestwick_536
Prestwick0_000125
Prestwick1_000125
Prestwick2_000125
Prestwick3_000125
PZC
SAM002264637
Sch 3940
SCH-3940
SMR000058180
SPBio_001603
SPBio_002109
Spectrum_001610
SPECTRUM1503934
Spectrum2_001602
Spectrum3_000758
Spectrum4_000843
Spectrum5_001493
SR-01000000137-4
STK019818
STOCK1S-21551
Thilatazin
Tranquisan
Trifaron
Trilafon
Trilifan
Triphenot
UNII-FTA7XXY4EZ
WLN: T C666 BN ISJ EG B3- AT6N DNTJ D2Q
γ-(4-(β-hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine
Γ-(4-(β-hydroxyethyl)piperazin-1-yl)propyl-2-chlorophenothiazine
|
|
| 11 |
|
rituximab |
Approved |
Phase 3 |
|
174722-31-7 |
10201696 |
|
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
Ig gamma-1 chain C region
Mabthera
MabThera
|
Rituxan
rituximab
rituximab-abbs
rituximab-arrx
rituximab-pvvr
|
|
| 12 |
|
Pancrelipase |
Approved, Investigational |
Phase 3 |
|
53608-75-6 |
|
|
Synonyms:
lipase
Pancrealipase
Pancreatic extract pancrelipase
Pancreatic protease
|
Pancreatin
Pancreatinum
Pancrelipase (amylase
protease)
|
|
| 13 |
|
Everolimus |
Approved |
Phase 3 |
|
159351-69-6 |
6442177 70789204 |
|
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
001, RAD
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Certican
CERTICAN(R)
CHEMBL1201755
D02714
DB01590
everolimus
Everolimus
|
évérolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD, SDZ
RAD001
RAD-001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
RAD-001C
S1120_Selleck
SDZ RAD
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
|
|
| 14 |
|
Busulfan |
Approved, Investigational |
Phase 2, Phase 3 |
|
55-98-1 |
2478 |
|
Synonyms:
1, {4-Bis[methanesulfonoxy]butane}
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis(methanesulphonoxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Butanediol dimethanesulfonic acid
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethanesulphonic acid
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonoxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
acid, tetramethylene ester
AI3-25012
AKOS003614975
alkylating agent: crosslinks guanine residues
Ambap55-98-1
AN 33501
B1022
B2635_FLUKA
B2635_SIGMA
Bisulfex
Bisulphex
BRN 1791786
BSPBio_001920
Busilvex
busulfan
Busulfan
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Busulfan (JP15/USP/INN)
Busulfan [INN:JAN]
Busulfan glaxosmithkline brand
Busulfan GlaxoSmithKline Brand
Busulfan orphan brand
Busulfan Orphan Brand
Busulfan wellcome
Busulfan Wellcome
Busulfan wellcome brand
Busulfan Wellcome Brand
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Busulphano
Busulphanum
butane-1,4-diyl dimethanesulfonate
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
Citosulfan
CPD000058613
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
Glaxo wellcome brand OF busulfan
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline brand OF busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
|
GT 2041
GT 41
HMS1920I07
HMS2091O09
HMS502K09
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
Leucosulfan
Leucosulphan
LS-1358
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MLS001076666
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myléran
MYLERAN (TN)
Myleran tablets
Myleran Tablets
Myleran, Busulfex, Busulfan
Mylerlan
n-Butane-1,3-di(methylsulfonate)
N-Butane-1,3-di(methylsulfonate)
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI60_041640
NCI-C01592
NCIMech_000192
NINDS_000847
NSC 750
NSC750
NSC-750
NSC-750sulphabutin
Orphan brand OF busulfan
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
Spectrum_000092
SPECTRUM1500152
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
ST50825921
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene {bis[methanesulfonate]}
Tetramethylene bis(methanesulfonate)
Tetramethylene bis(methanesulfonic acid)
Tetramethylene bis(methanesulphonate)
Tetramethylene bis(methanesulphonic acid)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene Dimethane Sulfonate
Tetramethylenester kyseliny methansulfonove
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
Wellcome brand OF busulfan
Wellcome Brand of Busulfan
Wellcome, busulfan
Wellcome, Busulfan
WLN: WS1&O4OSW1
X 149
|
|
| 15 |
|
Ginseng |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
50647-08-0 |
|
|
Synonyms:
Aralia ginseng root
Asian ginseng root
Chinese ginseng root
Ginseng (panax ginseng)
Ginseng extract
Ginseng, asian
Hong shen root
Insam root
Korean ginseng
Korean ginseng root
Ninjin root
|
Panax ginseng
Panax ginseng root
Panax ginseng root extract
Panax schinseng root
Panax verus root
Red ginseng
Ren seng root
Ren shen
Ren shen root
True ginseng root
|
|
| 16 |
|
Ferric Oxide, Saccharated |
|
Phase 3 |
|
|
|
| 17 |
|
Adjuvants, Immunologic |
|
Phase 2, Phase 3 |
|
|
|
| 18 |
|
ferric gluconate |
|
Phase 3 |
|
|
|
| 19 |
|
Iron Supplement |
|
Phase 3 |
|
|
|
| 20 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
| 21 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
| 22 |
|
Antipsychotic Agents |
|
Phase 3 |
|
|
|
| 23 |
|
GABA Agonists |
|
Phase 3 |
|
|
|
| 24 |
|
Anesthetics, Dissociative |
|
Phase 3 |
|
|
|
| 25 |
|
Antidepressive Agents |
|
Phase 3 |
|
|
|
| 26 |
|
Excitatory Amino Acid Antagonists |
|
Phase 3 |
|
|
|
| 27 |
|
Analgesics, Non-Narcotic |
|
Phase 3 |
|
|
|
| 28 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
| 29 |
|
Amitriptyline, perphenazine drug combination |
|
Phase 3 |
|
|
|
| 30 |
|
Antidepressive Agents, Tricyclic |
|
Phase 3 |
|
|
|
| 31 |
|
Liver Extracts |
|
Phase 3 |
|
|
|
| 32 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
| 33 |
|
pancreatin |
|
Phase 3 |
|
|
|
| 34 |
|
polysaccharide-K |
|
Phase 3 |
|
|
|
| 35 |
|
Thymoglobulin |
|
Phase 2, Phase 3 |
|
|
|
| 36 |
|
Mechlorethamine |
Approved, Investigational |
Phase 2 |
|
51-75-2 |
4033 |
|
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichlorodiethyl-methylamine
2,2'-Dichloro-N-me
2,2'-dichloro-N-methyldiethylamine
2,2'-Dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
b,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
beta,Beta'-dichlorodiethyl-N-methylamine
bis(2-chloroethyl)methylamine
Bis(2-chloroethyl)methylamine
Bis(b-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
bis(β-chloroethyl)methylamine
Bis(β-chloroethyl)methylamine
BRN 0605323
BSPBio_001947
C07115
C5H11Cl2N
Carolysine
Caryolysin
Caryolysine
CCRIS 447
CHEBI:28925
CHEMBL427
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum
Chlormethinum [INN-Latin]
CID4033
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
Embechine
Embichin
ENT-25294
HMS1920J15
HMS2091B04
HMS502F21
HN2
HN-2
HSDB 5083
Hydrochloride N-oxide, mechlorethamine
Hydrochloride, mechlorethamine
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
mechlorethamine
Mechlorethamine
|
Mechlorethamine hydrochloride
Mechlorethamine hydrochloride N oxide
Mechlorethamine hydrochloride N-oxide
Mechlorethamine N oxide
Mechlorethamine N-oxide
Mechlorethamine oxide
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Merck brand OF mechlorethamine hydrochloride
Merck frosst brand OF mechlorethamine hydrochloride
methylbis(2-chloroethyl)amine
Methylbis(2-chloroethyl)amine
Methylbis(b-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
methylbis(β-chloroethyl)amine
Methylbis(β-chloroethyl)amine
Methylchlorethamine
Methyldi(2-chloroethyl)amine
Mitomen
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)methylamine
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Di(chloroethyl)methylamine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogen mustard N oxide
Nitrogen mustard N-oxide
Nitrogranulogen
Nitromin
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-methyl-bis(2-chloroethyl)amine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(b-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-methyl-bis(β-chloroethyl)amine
N-Methyl-bis(β-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-Oxide, mechlorethamine hydrochloride
N-Oxide, nitrogen mustard
NSC 762
NSC762
NSC-762
SPBio_000496
Spectrum_000889
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
thyldiethylamine
TL 146
UNII-50D9XSG0VR
Î’,beta'-dichlorodiethyl-N-methylamine
β,β'-dichlorodiethyl-N-methylamine
|
|
| 37 |
|
Melphalan |
Approved |
Phase 2 |
|
148-82-3 |
4053 460612 |
|
Synonyms:
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
148-82-3
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3025 c.b
3025 C.B.
3223-07-2
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-(Bis(2-chloroethyl)amino)phenylalanine
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
AC1LA2OE
Alanine Nitrogen Mustard
Alkeran
ALKERAN (TN)
AmbotzHAA1563
At-290
AY3360000
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
Levofalan
Levofolan
Levopholan
L-PAM
L-Phenylalanine mustard
LS-15868
LS-865
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
M2011_SIGMA
|
Medphalan
Melfalan
Melfalano
Melfalano [INN-Spanish]
melphalan
Melphalan
Melphalan (JP15/USP/INN)
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
Merphalan
MLS001333666
MLS002153368
MolPort-003-665-535
Mustard, phenylalanine
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC241286
NSC8806
NSC-8806
p-Bis(b-chloroethyl)aminophenylalanine
p-Bis(beta-chloroethyl)aminophenylalanine
p-Bis(β-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
phenylalanine nitrogen mu stard
Phenylalanine nitrogen mustard
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N,N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-di(chloroethyl)aminophenylala nine
p-N-Di(chloroethyl)aminophenylalanine
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
Sarcolysine
Sarkolysin
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
Spectrum_000397
SPECTRUM1500382
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
|
|
| 38 |
|
Mesna |
Approved, Investigational |
Phase 2 |
|
3375-50-6 |
598 |
|
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-mercaptoethanesulfonic acid
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-mercaptoethanesulphonic acid
2-Mercaptoethanesulphonic acid
2-mercaptoethylsulfonate
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-sulfanylethylsulfonate
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
Bristol myers squibb brand OF mesna
|
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzima M
Coenzym m
Coenzym M
Coenzyme m
CoM
HS-CoM
Kendrick brand OF mesna
Mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
reduced coenzyme M
Reduced coenzyme m
reduced CoM
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
Î’-mercaptoethanesulfonate
β-mercaptoethanesulfonic acid
Î’-mercaptoethanesulfonic acid
Î’-mercaptoethanesulphonate
Î’-mercaptoethanesulphonic acid
|
|
| 39 |
|
Pentostatin |
Approved, Investigational |
Phase 2 |
|
53910-25-1 |
40926 439693 |
|
Synonyms:
(8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4H-imidazo[4,5-d][1,3]diazepin-8-ol
(R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol
2' Deoxycoformycin
2'-DCF
2'-Deoxycoformycin
2'-Dexoycoformycin
53910-25-1
59979-24-7
AC1L97UQ
BIDD:GT0136
C02267
CHEBI:41829
CHEMBL1580
CI-825
CID439693
CL-67310465
Co vidarabine
Coforin
Co-V
Covidarabine
Co-vidarabine
CO-Vidarabine
|
D00155
DB00552
dCF
Deoxycoformycin
Lederle brand OF pentostatin
Nipent
Nipent (TN)
Oncopent
PD-81565
PD-ADI
pentostatin
Pentostatin
Pentostatin (JAN/USAN/INN)
Pentostatina
Pentostatine
Pentostatinum
Prasfarma brand OF pentostatin
Supergen brand OF pentostatin
Vidarbine
Vira A deaminase inhibitor
Warner-lambert brand OF pentostatin
Wyeth brand OF pentostatin
|
|
| 40 |
|
Leflunomide |
Approved, Investigational |
Phase 2 |
|
75706-12-6 |
3899 |
|
Synonyms:
210165-51-8
4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl
4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl)
5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide
5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide)
5-Methylisoxazole-4-carboxylate (4-trifluoromethyl)anilide
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide
5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide
75706-12-6
a,a,a-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
A77 1486
AB00052389
AC1L1GYK
AC1Q2EVA
AC-6796
AKOS000265193
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
AP-501/42475599
Arava
Arava (TN)
Arava, Leflunomide
Aventis behring brand OF leflunomide
Aventis Behring Brand of Leflunomide
Aventis brand OF leflunomide
Aventis Brand of Leflunomide
Aventis pharma brand OF leflunomide
Aventis Pharma Brand of Leflunomide
BIDD:PXR0189
BPBio1_000930
BRD-K78692225-001-03-9
BSPBio_000844
C045463
C07905
CAS-75706-12-6
CHEBI:6402
CHEMBL960
CID3899
D00749
DB01097
DivK1c_000916
EU-0100649
HMS1570K06
HMS1922M06
HMS2090O12
HMS502N18
Hoechst brand OF leflunomide
Hoechst Brand of Leflunomide
HSDB 7289
HWA 486
HWA-486
I06-2131
IDI1_000916
KBio1_000916
KBio2_000802
KBio2_003370
KBio2_005938
|
KBioSS_000802
L 5025
L5025_SIGMA
Leflunomid
Leflunomida
Leflunomida [INN-Spanish]
leflunomide
Leflunomide
Léflunomide
Leflunomide (JAN/USAN/INN)
Leflunomide [USAN:INN]
Leflunomidum
Leflunomidum [INN-Latin]
lefunamide
Lefunomide [Inn-Spanish]
Lefunomide [INN-Spanish]
Lopac0_000649
Lopac-L-5025
LS-86580
MLS000069648
MLS-0003109.0001
MLS001076267
MolPort-002-345-613
N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide
N-(4-Trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide
NCGC00015610-01
NCGC00015610-02
NCGC00015610-03
NCGC00015610-07
NCGC00015610-12
NCGC00022625-03
NCGC00022625-04
NCGC00022625-05
NCGC00022625-06
NCGC00022625-07
NCGC00022625-08
NINDS_000916
NSC677411
Prestwick_87
Prestwick0_000772
Prestwick1_000772
Prestwick2_000772
Prestwick3_000772
RS-34821
S1247_Selleck
SMR000058209
SPBio_002783
Spectrum_000322
SPECTRUM1503927
Spectrum5_000850
SU 101
SU 101 (pharmaceutical)
SU101
SU-101
TL8005179
UNII-G162GK9U4W
ZINC00004840
Α,α,α-trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
|
|
| 41 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4 |
60750 |
|
Synonyms:
103882-84-4
122111-03-9
2',2'-DFDC
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFdC
DFDC
DFdCyd
Folfugem
Gamcitabine
Gemcel
Gemcin
Gemcitabin
Gemcitabina
|
Gemcitabina [INN-Spanish]
gemcitabine
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
GemLip
Gemtro
Gemzar
Gemzar (hydrochloride)
GEO
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY188011
LY-188011
NCGC00168784-01
NChemBio.2007.10-comp25
nchembio.573-comp7
nchembio.90-comp2
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
Zefei
ZINC18279854
|
|
| 42 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
|
|
Synonyms:
|
| 43 |
|
Cisplatin |
Approved |
Phase 2 |
|
15663-27-1 |
84093 441203 2767 |
|
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatin
Cisplatine
cisplatino
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
|
CPDC
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
| 44 |
|
Azacitidine |
Approved, Investigational |
Phase 1, Phase 2 |
|
320-67-2 |
9444 |
|
Synonyms:
2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one
320-67-2
4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz
4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
4-Amino-1-b-D-ribofuranosyl-S-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one
4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one
4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one
4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one
4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one
4-Amino-1-β-D-ribofuranosyl-S-triazin-2(1H)-one
5 Azacytidine
5 AZC
5-AC
5AzaC
5-AZAC
5-azacitidine
5-aza-CR
5-azacytidine
5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine
5-AZCR
A 2385
A1287_SIGMA
A2385_SIGMA
AC1L1T1Y
Antibiotic U 18496
Azacitidina
Azacitidina [INN-Spanish]
Azacitidine
Azacitidine (JAN/USAN/INN)
Azacitidine [USAN:INN]
Azacitidinum
Azacitidinum [INN-Latin]
Azacytidine
BCBcMAP01_000083
BRN 0620461
BSPBio_003157
C11262
CCRIS 60
CHEBI:2038
CHEMBL1489
CID9444
cMAP_000082
CPD000857239
D001374
D03021
DB00928
DivK1c_000125
EINECS 206-280-2
EU-0100035
FT-0081170
HMS1921J22
HMS2092D08
HMS500G07
HSDB 6879
IDI1_000125
InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1
|
Jsp005945
KBio1_000125
KBio2_001742
KBio2_002556
KBio2_004310
KBio2_005124
KBio2_006878
KBio2_007692
KBio3_002657
KBio3_003034
KBioGR_001444
KBioGR_002556
KBioSS_001742
KBioSS_002565
Ladakamycin
Lopac0_000035
LS-1189
MLS001333121
MLS001333122
MLS002153249
MolMap_000062
mylo sar
Mylosar
NCGC00090851-01
NCGC00090851-02
NCGC00090851-03
NCGC00090851-04
NCGC00090851-08
NCGC00178234-01
NCI-C01569
NINDS_000125
NS-17
NSC 102816
NSC102816
NSC-102816
Pharmion brand OF azacitidine
Pharmion Brand of Azacitidine
pyrimidine antimetabolite: inhibits nucleic acid replication
S1782_Selleck
SAM002264595
SMR000857239
SPBio_000892
Spectrum_001262
SPECTRUM1502111
Spectrum2_000786
Spectrum3_001509
Spectrum4_000922
Spectrum5_001166
ST056940
s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI)
TL80073599
U 18496
U-18496
UNII-M801H13NRU
Vidaza
Vidaza (TN)
wr 183027
WR-183027
ZINC03861768
|
|
| 45 |
|
Cytarabine |
Approved, Investigational |
Phase 1, Phase 2 |
|
147-94-4 |
6253 |
|
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
147-94-4
1-Arabinofuranosylcytosine
1-b-D-Arabinofuranosylcytosine
1beta -Arabinofuranasylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta -D-Arabinofuranosylcytosine
1-beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosyl-cytosine
1-beta-D-Arabinofuranosylcytosine, cytosine arabinoside
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1beta-D-Arabinosylcytosine
1-beta-D-Arabinosylcytosine
1-beta-D-Arabinosyl-cytosine
1-Î’-D-arabinofuranosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2(1H)-pyrimidinone
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
4-Amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
4-Amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
Alexan
AR3
Ara C
Arabinocytidine
Arabinocytosine
Arabinofuranosylcytosine
Arabinoside C
Arabinoside, cytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
AraC
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Aracytidine
Ara-Cytidine
Aracytin
Aracytine
Arafcyt
beta Ara C
beta -Arabinosylcytosine
beta -Cytosine arabinoside
beta -D-Arabinosylcytosine
beta-Ara c
beta-Ara C
beta-Arabinosylcytosine
beta-Cytosine arabinoside
Beta-cytosine arabinoside
beta-D-Arabinosylcytosine
BIDD:GT0371
BIDD:PXR0139
BTB15125
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
Citarabina
|
Citarabina [INN-Spanish]
CPD000449317
Cytarabin
Cytarabina
cytarabine
Cytarabine
Cytarabine (JP15/USP/INN)
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine hydrochloride
cytarabine liposome injection
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar u
Cytosar-u
CytosarU
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-b-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-1-β-D-arabinofuranoside
Cytosinearabinoside
Cytosine-b-D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta -D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosine-beta-D-arabinofuranoside
cytosine-β-D-arabinofuranoside
Cytosine-β-D-arabinofuranoside
D00168
DB00987
Depocyt
Depocyt (liposomal)
Depocyt (TN)
Depocyte
DepoCyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Hydrochloride, cytarabine
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
Lopac0_000316
LS-860
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
Spongocytidine
SR-01000075773-3
Tarabine
TL8001048
U 19920A
U-19,920
U-19920
Udicil
UNII-04079A1RDZ
ZINC03795098
|
|
| 46 |
|
nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
|
Synonyms:
BMS-936558
MDX-1106
nivolumab
|
|
|
| 47 |
|
Etoposide |
Approved |
Phase 2 |
|
33419-42-0 |
36462 |
|
Synonyms:
(−)-etoposide
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4-demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
alpha-D-Glucopyranosyl isomer etoposide
Ambap33419-42-0
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bio1_000489
Bio1_000978
Bio1_001467
BPBio1_000673
BRD-K37798499-001-02-5
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
BSPBio_000611
C01576
CCRIS 2392
Celltop
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl epipodophyllotoxin ethylidine glucoside
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
Eto gry
Eto-gry
Etomedac
ETOP
Etopol
Etopophos
Etopophos (phosphate salt)
Etopos
etoposide
|
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido [INN-Spanish]
Etoposido ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Etosid
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
Lastet
Lemery brand OF etoposide
LS-1214
Medac brand OF etoposide
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
nchembio.573-comp8
nchembio873-comp2
NK 171
Novartis brand OF etoposide
NSC 141540
NSC141540
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Prestwick_211
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Riboposid
Ribosepharm brand OF etoposide
S1225_Selleck
SAM001246880
Sanfer brand OF etoposide
SMR000112002
SPBio_002532
ST056353
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Teva, etoposide
Toposar
trans-Etoposide
UNII-6PLQ3CP4P3
Vepesid
VePesid
VePESID (TN)
Vepesid J
Vepeside
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16 (pharmaceutical)
VP 16213
VP 16-213
VP-16
VP-16-213
ZINC03830818
ZINC03938684
Zuyeyidal
|
|
| 48 |
|
Dexamethasone acetate |
Approved, Investigational, Vet_approved |
Phase 2 |
|
1177-87-3 |
|
|
Synonyms:
16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate
9alpha-Fluoro-16alpha-methylprednisolone acetate
Dexamethasone 21-acetate
|
Dexamethasone acetate anhydrous
Dexamethasone acetate, anhydrous
Dexamethasoni acetas
|
|
| 49 |
|
Oxaliplatin |
Approved, Investigational |
Phase 2 |
|
61825-94-3 |
5310940 9887054 6857599 43805 |
|
Synonyms:
ACT 078
ACT-078
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Eloxatine
Elplat
Foloxatine
L-OHP
L-OHP CPD
|
Oxalatoplatin
Oxalatoplatinum
oxaliplatin
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
|
|
| 50 |
|
Dexamethasone |
Approved, Investigational, Vet_approved |
Phase 2 |
|
50-02-2 |
5743 |
|
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
137098-19-2
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16a-Methyl-9a-fluoro-1-dehydrocortisol
16α-Methyl-9α-fluoro-1-dehydrocortisol
16Α-methyl-9α-fluoro-1-dehydrocortisol
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16a-methyl-9a-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9a-Fluoro-16a-methylprednisolone
9a-Fluoro-16BETA-methylprednisolone
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-Fluoro-16alpha-methyl-prednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9α-Fluoro-16α-methylprednisolone
9Α-fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
Adexone
Aeroseb-D
Aeroseb-dex
Aeroseb-Dex
AI3-50934
Ak dex OPH otic soln 0.1%
Alcon brand OF dexamethasone
Alcon Brand of Dexamethasone
alpha -Fluoro-16-alpha -methylcortisol
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (veterinary)
Azium (Veterinary)
BIDD:ER0494
BIDD:PXR0060
Bisu Ds
Bisu DS
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
C15643
C22H29FO5
Calonat
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
Corson
Corsone
Cortisumman
CPD001227192
CPD-10549
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-La
Decadron-LA
Decagel
Decaject
Decaject l.a.
Decaject L.A.
Decaject-l.a.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [Dcit]
Desametasone [DCIT]
Desamethasone
Desameton
Deseronil
DEX
Dexa
DEXA
Dexa mamallet
Dexa Mamallet
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexa-cortidelt
Dexa-Cortidelt
Dexacortin
Dexa-cortisyl
Dexa-Cortisyl
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexa-Mamallet
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
dexamethasone
Dexamethasone
Dexaméthasone
Dexamethasone (JP15/USP/INN)
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
|
Dexamethasone Acetate
Dexamethasone alcohol
Dexamethasone Alcohol
Dexamethasone base
Dexamethasone Base
Dexamethasone intensol
Dexamethasone Intensol
Dexamethasone sodium phosphate
Dexamethasone Sodium Phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexa-scheroson
Dexa-Scheroson
Dexa-sine
Dexa-Sine
Dexason
Dexasone
Dexasone 0.5MG
Dexasone 0.75MG
Dexasone 4MG
Dexasporin
Dex-ide
Dex-Ide
Dexinolon
Dexinoral
Dexone
Dexone 0.5
DEXONE 0.5
Dexone 0.75
DEXONE 0.75
Dexone 1.5
DEXONE 1.5
Dexone 4
DEXONE 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
DXM
Dxms
DXMS
ECR brand OF dexamethasone
ECR Brand of Dexamethasone
EINECS 200-003-9
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy brand OF dexamethasone
Foy Brand of Dexamethasone
FT-0080377
Gammacorten
Hexadecadrol
Hexadrol
Hexadrol elixir
Hexadrol Elixir
Hexadrol Tablets
Hl-dex
Hl-Dex
HL-Dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
I06-1196
ICN brand OF dexamethasone
ICN Brand of Dexamethasone
IontoDex
Isopto-dex
Isopto-Dex
Lokalison F
Loverine
LS-7300
Luxazone
Maxidex
Maxidex ont 0.1%
Maxidex sus 0.1%
Maxitrol
Mediamethasone
Merck brand OF dexamethasone
Merck Brand of Dexamethasone
Merz brand 1 OF dexamethasone
Merz Brand 1 of Dexamethasone
Merz brand 2 OF dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MK 125
MLS001055412
MLS001332507
MLS001332508
MolMap_000018
MolPort-003-846-433
Mymethasone
Naquasone (veterinary)
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
nchembio809-comp2
NCI60_003067
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
NSC 34521
NSC34521
Ocu-trol
Ocu-Trol
Oradexon
OTO-104
Pet derm III
Pet Derm Iii
Pet Derm III
Pet-Derm Iii
PHL-Dexamethasone
PMS Dexamethasone elixir 0.5mg/5ML
PMS-Dexamethasone
Policort
Posurdex
Prednisolon F
Prednisolone F
Prodex
S1322_Selleck
SAM002548948
Sandoz dexamethasone
SGCUT00126
Sk-Dexamethasone
SK-Dexamethasone
SMP1_000092
SMR000857119
SMR001227192
Spectrum5_002019
Spoloven
ST50307091
Sunia sol D
Sunia Sol D
Superprednol
TL8003317
to_000038
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
|
|
Interventional clinical trials:
(show top 50)
(show all 206)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. |
Unknown status |
NCT01698866 |
Phase 4 |
|
| 2 |
Quality of Life Related Response to Treatment in Anemic Cancer Patients Receiving Recormon and Efficacy of the Drug Dosage 30,000 IU Once Weekly in Patients With Lymphoproliferative Disorders |
Completed |
NCT00776425 |
Phase 4 |
Epoetin beta |
| 3 |
Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) |
Completed |
NCT01088724 |
Phase 4 |
fludarabine, cyclophosphamide, doxorubicin, rituximab |
| 4 |
Cytotoxic T Cell Therapy for Post Transplant Lymphoproliferative Disease: Randomized Controlled Trial in Transplant Recipients |
Unknown status |
NCT00033475 |
Phase 3 |
|
| 5 |
Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation |
Unknown status |
NCT01800643 |
Phase 2, Phase 3 |
|
| 6 |
Phase 3 Study of Recombinant Erythropoetin and Adjuvant I.V. Iron Therapy of Anemic Patients With Lymphoproliferative Disorders |
Completed |
NCT00145652 |
Phase 3 |
Neo-Recormon and Venofer |
| 7 |
Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated Donors |
Completed |
NCT00354120 |
Phase 2, Phase 3 |
Alentuzumab;Globulina antilinfocitaria |
| 8 |
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer |
Completed |
NCT00058331 |
Phase 3 |
|
| 9 |
Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) |
Completed |
NCT00750009 |
Phase 3 |
|
| 10 |
The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study |
Completed |
NCT00719563 |
Phase 3 |
American ginseng |
| 11 |
Predictive Value of the "Cytocapacity Test" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy |
Completed |
NCT01085058 |
Phase 2, Phase 3 |
lenograstim |
| 12 |
A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy |
Completed |
NCT00070382 |
Phase 3 |
darbepoetin alfa;epoetin alfa |
| 13 |
A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement |
Completed |
NCT00053053 |
Phase 3 |
|
| 14 |
Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. |
Completed |
NCT00666211 |
Phase 3 |
|
| 15 |
A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia |
Completed |
NCT00661999 |
Phase 3 |
sodium ferric gluconate complex in sucrose |
| 16 |
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study |
Completed |
NCT00516503 |
Phase 3 |
baclofen/amitriptyline/ketamine gel |
| 17 |
Open-label Extension Study With Tadekinig Alfa (r-hIL-18BP) to Monitor Safety and Tolerability in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency |
Recruiting |
NCT03512314 |
Phase 3 |
Tadekinig alfa |
| 18 |
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy |
Recruiting |
NCT03394365 |
Phase 3 |
|
| 19 |
Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial With Tadekinig Alfa (r-hIL-18BP) in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency |
Recruiting |
NCT03113760 |
Phase 3 |
Tadekinig alfa |
| 20 |
Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab |
Recruiting |
NCT03392142 |
Phase 3 |
|
| 21 |
Phase III Multicenter Open-label Randomized Clinical Trial Comparing Everolimus and Low Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil at 6 mo Post-Transplant to Prevent Long-term Complications After Pediatric Heart Transplantation |
Active, not recruiting |
NCT03386539 |
Phase 3 |
Everolimus;Tacrolimus;Mycophenolate Mofetil |
| 22 |
In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders |
Terminated |
NCT00176826 |
Phase 2, Phase 3 |
Myeloablative conditioning regimen |
| 23 |
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Alemtuzumab (Campath) |
Unknown status |
NCT00345345 |
Phase 2 |
|
| 24 |
Phase II Trial of Rituximab in Patients With B-Cell Lymphoproliferative Disorders Associated With Pharmacologic Immunosuppression |
Unknown status |
NCT00003716 |
Phase 2 |
|
| 25 |
An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases |
Completed |
NCT00002663 |
Phase 1, Phase 2 |
|
| 26 |
A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies |
Completed |
NCT01498484 |
Phase 2 |
|
| 27 |
A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes |
Completed |
NCT00001438 |
Phase 2 |
all-trans-retinoic acid with IFN-alpha2a |
| 28 |
Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders |
Completed |
NCT00023764 |
Phase 2 |
bortezomib |
| 29 |
A Phase II Study of the Novel Proteasome Inhibitor Bortezomib in Combination With Rituximab, Cyclophosphamide and Prednisone in Patients With Relapsed/Refractory Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma (MCL) |
Completed |
NCT00295932 |
Phase 1, Phase 2 |
bortezomib;cyclophosphamide;prednisone |
| 30 |
A Multicenter Phase II Study Of BMS 247550 (Epothilone B Analogue) In Indolent Lymphoproliferative Disorders |
Completed |
NCT00052572 |
Phase 2 |
ixabepilone |
| 31 |
Open Label Multicenter Study of Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) |
Completed |
NCT01610180 |
Phase 2 |
Eltrombopag Olamine |
| 32 |
A Phase I/II Study: Zevalin Radioimmunotherapy for Patients With Post Transplant Lymphoproliferative Disease Following Solid Organ Transplantation |
Completed |
NCT00064246 |
Phase 1, Phase 2 |
|
| 33 |
Phase II Study of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults With B-lymphocyte Antigen CD20 (CD20) Positive Post-Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT) |
Completed |
NCT00066469 |
Phase 2 |
cyclophosphamide;methylprednisolone;prednisone |
| 34 |
Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (PTLD-1/3) |
Completed |
NCT00590447 |
Phase 2 |
rituximab monotherapy;sequential R-CHOP |
| 35 |
A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation |
Completed |
NCT01427881 |
Phase 2 |
cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan |
| 36 |
High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma |
Completed |
NCT01177371 |
Phase 2 |
busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine |
| 37 |
Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy |
Completed |
NCT00255749 |
Phase 2 |
|
| 38 |
A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil |
Completed |
NCT00089011 |
Phase 2 |
fludarabine phosphate;mycophenolate mofetil;tacrolimus |
| 39 |
RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa |
Completed |
NCT00416624 |
Phase 2 |
darbepoetin alfa;epoetin alfa |
| 40 |
Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancy, Using MHC Identical or Near Identical Donors and Sub-Myeloablative Conditioning With CAMPATH 1H (DIMSUM) |
Completed |
NCT00048412 |
Phase 1, Phase 2 |
FLUDARABINE;CAMPATH 1H;FK50 |
| 41 |
Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil |
Completed |
NCT00006251 |
Phase 1, Phase 2 |
fludarabine phosphate;cyclosporine;mycophenolate mofetil |
| 42 |
Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD) |
Completed |
NCT01058239 |
Phase 2 |
bortezomib;rituximab |
| 43 |
Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies |
Completed |
NCT01839916 |
Phase 2 |
|
| 44 |
A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation |
Completed |
NCT01789255 |
Phase 2 |
vorinostat;tacrolimus;cyclosporine;methotrexate |
| 45 |
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial |
Completed |
NCT00078858 |
Phase 1, Phase 2 |
fludarabine phosphate;cyclosporine;mycophenolate mofetil |
| 46 |
Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation |
Completed |
NCT00049504 |
Phase 2 |
cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil |
| 47 |
A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy |
Completed |
NCT01075321 |
Phase 1, Phase 2 |
everolimus;lenalidomide |
| 48 |
Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma |
Completed |
NCT00436618 |
Phase 2 |
Everolimus |
| 49 |
CD-34 Selection for Ex-vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning |
Completed |
NCT00368355 |
Phase 2 |
Ara-C;Cyclophosphamide |
| 50 |
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism |
Completed |
NCT00176865 |
Phase 2 |
Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG) |
Search
NIH Clinical Center
for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood
|
